Analyst Scoreboard: 7 Ratings For Quest Diagnostics
Portfolio Pulse from Benzinga Insights
In the last three months, 7 analysts have published ratings on Quest Diagnostics (NYSE:DGX), with a mix of bullish, indifferent, and somewhat bearish perspectives. The average 12-month price target has risen by 3.77% to $148.57. Recent analyst actions include several rating raises and price target increases.
May 30, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quest Diagnostics has received mixed analyst ratings over the past three months, with a notable increase in the average 12-month price target by 3.77% to $148.57. Recent analyst actions include several rating raises and price target increases.
The increase in the average price target and multiple rating raises suggest a positive short-term outlook for Quest Diagnostics. Analysts' improved price targets indicate confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100